Communiqués Matricelf Ltd

Actions

Marché Fermé - TEL AVIV STOCK EXCHANGE 16:24:03 10/09/2026			Varia. 5j.	Varia. 1 janv.
266,50 ^ILa	-0,67 %		-11,08 %	-51,62 %

03/09	Matricelf reçoit un avis favorable de la FDA sur les éléments clés de son futur premier essai clinique humain pour le programme NewRal contre les lésions de la moelle épinière	CI
27/08	Matricelf Ltd publie ses résultats pour le semestre clos le 30 juin 2026	CI

03/09	Matricelf Receives FDA Feedback Supporting Key Elements of Proposed First in Human Clinical Trial for NewRal Spinal Cord Injury Program	PR
09/07	Matricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing Milestones	PR
23/06	Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury	AQ
03/03	Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	PR
02/03	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	AQ
27/02	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	PR
26/02	Matricelf Ltd. (TASE: MTLF) Reports 2025 Milestones and Outlines 2026 Strategic Roadmap Toward First-in-Human Spinal Cord Implantation	PR
21/08/25	Tel Aviv University: Israeli Breakthrough: First Human Trial of Engineered Spinal Cord	AQ
12/03/25	Cellino and Matricelf, New Hope for Spinal Cord Injuries	AQ
11/03/25	Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments	BU
27/03/24	Matricelf : INVESTORS PRESENTATION	PU